Award
NIH Reporter #5R01HL167912-05
Novel Inhibitors for Temporal Modulation of T-Lymphocytes during Chronic Heart Failure
Recipient
Pennsylvania State University Hershey Medical Center
Award Amount
$578,432.00
Ceiling
$578,432.00
Awarded
September 08, 2026
Identifier
5R01HL167912-05
NIH awarded a grant to Pennsylvania State University Hershey Medical Center to study novel inhibitors targeting T-lymphocytes for treating chronic heart failure, aiming to reduce cardiac remodeling and improve heart function.
Description
This NIH grant project focuses on developing novel inhibitors to modulate T-lymphocytes during chronic heart failure to reduce left ventricular remodeling and heart failure progression. The study evaluates the therapeutic efficacy of a novel ERĪ² agonist, OSU-ERb-012, in selectively inhibiting pathogenic CD4+ T-cells and improving cardiac function post-myocardial infarction.